Recurrence of breast carcinoma as Paget disease of the skin at a prior core needle biopsy site: Case report and review of the literature

Katherina Zabicki Calvillo a, Lifei Guo b, Valerie Brostrom c, Stuart J. Schnitt d, Xuefei Hong e, Sughra Raza f, Susan C. Lester c, *

a Department of Surgery, Brigham and Women’s Hospital, Boston, MA, United States
b Department of Plastic Surgery, Lahey Hospital and Medical Center, Burlington, MA, United States
c Department of Pathology, Brigham and Women’s Hospital, Boston, MA, United States
d Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States
e Brigham and Women’s Faulkner Hospital, Boston, MA, United States
f Department of Radiology, Brigham and Women’s Hospital, Boston, MA, United States

A R T I C L E   I N F O

Article history:
Received 21 July 2015
Received in revised form 26 August 2015
Accepted 27 August 2015
Available online 9 September 2015

Keywords:
Breast cancer
Paget disease
Needle biopsy
Needle track recurrence

A B S T R A C T

INTRODUCTION: Core needle biopsy has become the preferred method of diagnosing breast carcinomas prior to definitive surgery. The possibility of displacing tumor cells into the needle track is a concern.

PRESENTATION OF CASE: A 38 year old woman was diagnosed with right breast ductal carcinoma in situ (DCIS) with microinvasion by core needle biopsy. Bilateral skin sparing mastectomies with immediate autologous reconstruction were performed. One and a half years later the patient noted erythema and a scaling crust on the skin of the right breast that progressed over several months. Punch biopsy revealed Paget disease restricted to the epidermis. Subsequent comparison to initial clinical photographs confirmed the cancer was associated with the skin puncture site of the needle biopsy. The patient underwent complete excision with skin grafting and remains free of disease three years later.

DISCUSSION: Only 13 cases of needle track recurrences have been reported. The majority presented as invasive carcinoma forming a subcutaneous mass. In the current case, detection was delayed due to not initially noting that a skin lesion was at the puncture site of the original needle biopsy. This is the only case of recurrence as tumor limited to the epidermis.

CONCLUSION: Although recurrence in a needle track occurs very infrequently, clinicians should be aware of this phenomenon and investigate any changes, particularly when occurring at a needle biopsy site. Recording the skin puncture site can aid in early detection of recurrences. Recognition of a recurrence is important for prompt treatment and optimal prognosis.

© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Needle biopsies have become the preferred method for the initial evaluation of breast lesions. Patients with benign findings are spared surgical excision and patients with malignant findings can have definitive surgery planned. There has been a long-standing concern about the possibility of needle track seeding leading to local breast cancer recurrence [1]. Fortunately, recurrences in the needle track are exceedingly rare. We report the case of a woman treated for ductal carcinoma in situ DCIS and one focus of microinvasion with mastectomy and autologous reconstruction, who recurred with DCIS involving the epidermis (Paget disease of the skin) at the skin puncture site of the original core needle biopsy.

2. Case report

A 38 year old woman at high risk of breast cancer due to prior radiation for Hodgkin disease was discovered to have an area of calcifications in the lower inner quadrant of the right breast on her first screening mammogram. No skin lesions were present and the nipple was normal in appearance. A 10 gauge vacuum-assisted core needle biopsy successfully sampled the calcifications and a marking clip was placed. The needle entered the breast at approximately 5:00 (Fig. 1). The biopsy revealed high grade DCIS with comedo necrosis and calcifications. A single focus was suspicious for microinvasion. The DCIS was negative for estrogen receptor (ER), showed 1–4% positivity for progesterone receptor (PR), and was positive for HER2 (3+). Breast MRI showed a corresponding 2.5 × 1.0 cm area of enhancement in the area of the DCIS, located 5.3 cm away from the nipple.

The patient opted to undergo bilateral skin sparing mastectomies with immediate reconstruction using pedicled transverse

* Corresponding author at: Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, United States. Fax: +1 617 264 5118.
E-mail address: sleser@partners.org (S.C. Lester).
rectus abdominus myocutaneous (TRAM) flaps. The nipple and areolar complexes were removed, but the skin in the area of the prior needle biopsy site was preserved. The right mastectomy revealed DCIS with 2 foci of microinvasion over 3–4 cm. The skin, nipple, superficial skin flap margin, and deep margin were free of carcinoma, as were 3 sentinel nodes.

One and a half years after the mastectomy, the patient noted an area of skin change in the lower inner aspect of the right reconstructed breast (Fig. 2). This area was not close to the mastectomy scar or the reconstructed nipple. The lesion measured 1.2 cm but gradually increased in size and was treated by her primary care physician with topical antifungal medication. The skin lesion continued to enlarge and was brought to the attention of her breast surgical oncologist three years after her mastectomy. The erythematous lesion now measured 2.5 × 2.0 cm and appeared eroded (Fig. 3). Photographs taken by her plastic surgeon prior to her mastectomy and reconstruction fortuitously showed the skin puncture site of the original core needle biopsy (Fig. 1). It was apparent that the skin lesion was at this same site. A skin punch biopsy was performed and revealed tumor cells restricted to the epidermis (Paget disease).

The entire area of involved skin was excised to negative margins. Because of the size and location of the lesion, full thickness skin grafting was necessary for cosmetic closure. The carcinoma was restricted to the epidermis over a 1.7 cm area (Fig. 4). The carcinoma was negative for ER, showed low levels of PR, and was strongly positive for HER2. No invasion was present. No evidence of an ectopic nipple, Toker cells, residual breast tissue, or apocrine glands was seen. Therefore the most likely source of the tumor cells was iatrogenic displacement of tumor cells from the breast into the epidermis from the prior core needle biopsy. The patient is without
| Study                  | Biopsy type | Primary carcinoma | ER         | HER2       | Surgery | XRT | Systemic treatment | Time to recurrence | Recurrent carcinoma | Location of recurrence |
|-----------------------|-------------|-------------------|------------|------------|---------|-----|---------------------|--------------------|----------------------|-----------------------|
| Thurfjell et al. [7]  | FNA         | Adenoid cystic    | Unknown    | Unknown    | BCT     | No  | Unknown             | 4.1 years          | Adenoid cystic       | Breast                |
|                       | FNA         | mucinous          | Unknown    | Unknown    | BCT     | No  | Unknown             | 2.5 years          | mucinous            | Breast                |
|                       | FNA         | Invasive          | Unknown    | Unknown    | BCT     | No  | Unknown             | 2.1 years          | Invasive            | Breast                |
|                       | FNA         | tubuloductal      | Known      | Known      | BCT     | No  | Unknown             | 1.4 years          | tubuloductal         | Subcutaneous          |
|                       | FNA         | Invasive ductal   | +          | +          | M       | No  | AC, tam             | 1 year             | Invasive ductal      | Invasive ductal       |
|                       | FNA         | DCIS              | +          | +          | M       | No  | No                  | 2 years             | Invasive ductal      | Invasive ductal       |
|                       | FNA         | Invasive ductal   | +          | +          | M       | No  | Unknown             | 1.8 years           | Invasive ductal      | Dermis and subcutaneous |
|                       | FNA         | mucinous          | +          | −          | M SS    | No  | CMF                 | 1.9 years           | Invasive with mucin | Dermis and subcutaneous |
|                       | CNB         | Invasive ductal   | +          | −          | M SS    | No  | Unknown             | 1.3 years           | Invasive ductal      | Invasive ductal       |
|                       | CNB         | Not specified     | +          | +          | M SS    | No  | No                  | 1.2 years           | Not specified        | Subcutaneous          |
|                       | CNB         | Invasive ductal   | +          | +          | M SS    | No  | No                  | 1.1 years           | Invasive ductal      | Skin and dermis       |
|                       | CNB         | Invasive ductal/lobular | +         | −          | M SS    | No  | No                  | 3.9 years           | Well differentiated neuroendocrine tumor | Skin and subcutaneous tissue |
|                       | CNB         | Well differentiated | +          | −          | BCT     | No  | Aromatase inhibitor | 1.3 years           | neuroendocrine tumor | Paget disease (DCIS) |
|                       | CNB         | neuroendocrine    | +          | −          | BCT     | No  | Aromatase inhibitor | 1.5 years           | Paget disease (DCIS) | Epidermis             |

FNA, fine needle aspiration; stereo CNB, stereotactic core needle biopsy; DCIS, ductal carcinoma in situ; ER, estrogen receptor; BCT, breast conserving therapy; M, mastectomy; SS, skin sparing; XRT, radiation therapy; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; AC, adriamycin, cytoxan; tam, tamoxifen.
evidence of carcinoma, 3 years after the skin excision and 6 years after mastectomy.

3. Discussion

Adenocarcinoma between an intact basement membrane and an overlying normal epithelium is classified as Paget disease. The most common cause in the breast is DCIS extending from breast ducts into the epidermis of the nipple areolar complex. In the current case, the Paget disease was located away from the nipple and other etiologies had to be considered. Paget disease can arise from an ectopic nipple [2,3]. However, the location was far from the normal milk line along which ectopic nipples usually occur and a previously existing nipple was not observed. Extramammary Paget disease is thought to arise from apocrine glands, as it occurs in the genital, perianal, and axillary areas [4,5]. However, the recurrence was far from the axilla and no apocrine glands were present. Very rare cases of “ectopic” extramammary Paget disease occur in skin without apocrine glands and may arise from eccrine glands [6]. This disease most commonly involves the trunk of elderly males. No involvement of eccrine glands was seen in the current case.

The only likely remaining mechanism for this case of Paget disease is displacement of tumor cells from the original DCIS to the epidermis from tumor seeding the needle track. This possibility is supported by the identical histologic appearance and tumor marker expression of the original and recurrent carcinomas and the location at the core needle biopsy site.

Carcinoma recurring in a needle track as Paget disease of the skin has not been reported previously. There are only 13 other cases of breast cancer recurrence in a needle track after definitive surgery and a disease-free interval (Table 1) [7–13]. Eleven of the cases were invasive cancers, one was DCIS, and one was not specified. The time to recurrence ranged from 1 to 6 years (average 2.5 years). Three patients who underwent breast conservation recurred as invasive carcinoma in the breast and 1 recurred in the skin. Seven of 9 patients who underwent mastectomy recurred as invasive carcinomas involving the skin and subcutaneous tissue. One patient recurred as invasive carcinoma in skeletal muscle. The site of recurrence was not specified for 1 patient. All but 1 patient had carcinoma limited to the core needle site. This patient had multiple foci of carcinoma in the dermis in the same quadrant [10]. She had presented with 3 invasive carcinomas and had undergone 3 core needle biopsies.

Epithelial displacement into needle tracks immediately after the procedure has been shown to be quite common [1,14]. How then, does one explain the scarcity of clinically evident recurrences? The likelihood of finding cells in the needle track diminishes over time, supporting that, in many cases, these cells do not persist, perhaps due to lack of a developed blood supply [15]. It is also possible that radiation therapy plays a role, as none of the patients with needle track recurrences received this therapy. The possible role of systemic therapy is less clear. Two patients received chemotherapy, 6 did not, and this information is not provided for the other 5 patients (Table 1). Finally, removal of the needle track as part of the intended surgical resection or as a separate excision will eliminate any residual cells, though the utility of such a minor risk-reducing maneuver at the expense of likely cosmetic compromise may be debatable.

There are no definite risk factors for needle track recurrences. Needle track seeding has not been clearly associated with the type and size of needles, the number of needle passes, or the duration of the procedure [1]. Recurrences have been associated with both fine needle aspirations and core needle biopsies (Table 1). Although 5 of the cancers were of special histologic types, this association may be related to the decision not to radiate rather than the type of cancer.

The rarity of clinically diagnosed needle track recurrences supports that routine excision of the skin and needle track is not required, especially for women undergoing radiation therapy. It has been suggested that it would be helpful to document the site of the biopsy with a diagram or photograph in the patient’s medical record [12]. The location of the skin puncture site for a needle biopsy depends on the location of the lesion, the imaging modality used, and the size of the breast and cannot be determined with certainty unless recorded before the site heals. The need to document biopsy sites may be questioned due to the low number of reported recurrences. However, in the absence of knowing the location of the skin puncture, recurrences may be underreported. Documentation can also aid in early detection of recurrences. In the reported case, diagnosis was delayed for over a year as the skin lesion was mistaken for an infection. Fortunately, the carcinoma was detected while still in situ. Invasion can occur from Paget disease and the delay in diagnosis could have resulted in development of invasive carcinoma and a poorer prognosis [16,17].

The reported recurrences have been successfully treated with local excision and adjuvant treatment. Although follow-up is short, no cases have been reported with distant metastasis. It is important to recognize a skin recurrence as an isolated needle track recurrence, as this type of recurrence may not have the same dire prognosis for recurrent invasive carcinoma elsewhere in the chest wall [18,19].

4. Conclusions

Needle track recurrences after diagnosis and treatment of carcinoma are rare and have not been reported in patients receiving radiation therapy. For patients not receiving radiation, and whose needle track will not be removed by the planned surgery, documentation of the location of the skin puncture site in the patient’s chart may be of value. This can aid in the early detection of a recurrence as a subcutaneous mass or as changes in the skin. Early detection, especially for recurrences as DCIS as in the described case, can avoid possible poor clinical outcomes.

Conflict of interest

There are no conflicts of interest related to the contents of the submitted case report.

Funding

There are no sources of funding.

Ethical approval

This case report concerns one patient who is under the personal care of two of the authors (KZC and LG). The patient has provided written consent for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of the journal on request.

Authors contribution

Katherina Zabicki Calvillo, MD: Surgeon, consenting patient, reviewing and editing drafts of manuscript.
Lifei Guo, MD, PhD: Surgeon, clinical photographs, reviewing and editing drafts of manuscript.
Valerie Brostrom, MD: Review of pathology, reviewing and editing drafts of manuscript.
Stuart J Schnitt, MD: Review of pathology, reviewing and editing drafts of manuscript.
Xuefei Hong, MD: Review of pathology, reviewing and editing drafts of manuscript.

Sughra Raza, MD: Review of imaging information, reviewing and editing drafts of manuscript.

Susan C. Lester: Review of pathology, literature review, preparation of manuscript.

Guarantor

Susan C. Lester, MD, PhD.

Acknowledgements

The authors wish to thank the patient for allowing her case to be presented and to Peter van der Meer for translation of a reference.

References

[1] C.F. Loughran, C.R. Keeling, Seeding of tumour cells following breast biopsy: a literature review, Br. J. Radiol. 84 (2011) 869–874.
[2] G.F. Kao, J.H. Graham, E.B. Helwig, Paget’s disease of the ectopic breast with an underlying intraductal carcinoma: report of a case, J. Cutan. Pathol. 13 (1986) 59–66.
[3] M. Decaussin, M. Laville, P. Mathevet, L. Frappart, Paget’s disease versus Toker cell hyperplasia in a supernumerary nipple, Virchows Archiv. 432 (1998) 289–291.
[4] M. El Khoury, L. Lalonde, J. David, B. Issa-Chergui, L. Peloquin, L. Trop, Paget’s disease of the axilla arising from an underlying accessory mammary tissue, Clin. Radiol. 66 (2011) 575–577.
[5] A. Oliveira, M. Sanches, M. Selores, Axillary Paget’s disease associated with breast carcinoma in an elderly patient, EJD 21 (2011) 102–103.
[6] Y. Sawada, T. Bito, R. Kabashima, R. Yoshiki, R. Hino, M. Nakamura, M. Shiraishi, Y. Tokura, Ectopic extramammary Paget’s disease: case report and literature review, Acta Dermato Venereol. 50 (2010) 2–505.
[7] M.G. Thurfjell, T. Jansson, H. Nordgren, J. Bergh, A. Lindgren, L. Thurfjell, Local breast cancer recurrence caused by mammographically guided punctures, Acta Radiol. 41 (2000) 435–440.
[8] C. Chao, M.H. Torosian, M.C. Boraas, E.R. Sigurdson, J.P. Hoffman, B.L. Eisenberg, B. Fowble, Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature, Breast J. 7 (2001) 124–127.
[9] M. Intra, G. Mazzarol, M. Rietjens, J.A. Diaz Brito, R. Gennari, J. Soteldo, J. Rodriguez, G. Bassani, F. Bassi, Extramammary recurrence of DCIS after total mastectomy: an iatrogenic displacement following needleling procedures? Breast J. 11 (2005) 297–300.
[10] J.L. Uriburu, H.D. Vuoto, L. Cogorno, J.A. Isetta, G. Gandas, G.C. Imach, O.S. Bernabo, Local recurrence of breast cancer after skin-sparing mastectomy following core needle biopsy: case reports and review of the literature, Breast J. 12 (2006) 194–198.
[11] S. Kwo, J.C. Grotting, Does stereotactic core needle biopsy increase the risk of local recurrence of invasive breast cancer? Breast J. 12 (2006) 191–193.
[12] O.R. Brouwer, M. Donker, L.A. Woerdman, M.J. Vrancxen Peeters, Local recurrence after skin-sparing mastectomy [Article in Dutch]. Ned. Tijdschr. Geneeskd. 156 (2012) 1256–1259.
[13] T. Kawasaki, M. Ishida, T. Tada, H. Matsuya, M. Saitoh, Well-differentiated neuroendocrine tumor of the breast with recurrence due to needle tract seeding, Virchows Archiv. 466 (2015) 479–481.
[14] T. Uematsu, M. Kasami, The use of positive core wash cytology to estimate potential risk of needle tract seeding of breast cancer: directional vacuum-assisted biopsy versus automated core needle biopsy, Breast Cancer 17 (2010) 61–67.
[15] L.K. Diaz, E.J. Wiley, L.A. Venta, Are malignant cells displaced by large-gauge needle core biopsy of the breast? AJR 173 (1999) 1303–1313.
[16] X. Duan, N. Snege, A.E. Gullet, V.G. Prieto, E. Resetkova, I.M. Andino, Y. Wu, M.Z. Gilcrease, I. Bedrosian, S. Dawood, B. Arun, C.T. Albarracin, Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast, Am. J. Surg. Pathol. 36 (2012) 1353–1358.
[17] M.A. Sanders, L. Dominici, C. Denison, M. Golshan, T. Wiecorck, S.C. Lester, Paget disease of the breast with invasion from nipple skin into the dermis: an unusual type of skin invasion not associated with an adverse outcome, Arch. Pathol. Lab. Med. 137 (2013) 72–76.
[18] J.L. Wapnir, S.J. Anderson, E.P. Mamounas, I. Geyer, C.E. r, J.-H. Jeong, E. Tan-Chiu, B. Fisher, N. Wolmark, Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials, J. Clin. Oncol. (2006) 2028–2037.
[19] S. Aebi, S. Gelber, S.J. Anderson, I. Lang, A. Robidoux, M. Martin, J.W. Nortier, A.H. Paterson, M.F. Rimawi, J.M. Canada, B. Thurlimann, E. Murray, E.P. Maounas, C.E. Geyer Jr., K.N. Price, A.S. Coates, R.D. Gelber, P. Rastogi, N. Wolmark, I.L. Wapnir, CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomized trial, Lancet Oncol. 15 (2014) 156–163.